Flesinoxan

Source: Wikipedia, the free encyclopedia.
Flesinoxan
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 4-fluoro-N-(2-{4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide
JSmol)
  • C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO
  • InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1
  • Key:NYSDRDDQELAVKP-SFHVURJKSA-N

Flesinoxan (DU-29,373) is a

antihypertensive drug,[1][2][4] flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests.[5][6] As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability.[7][8] However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.[9]

In patients, flesinoxan enhances

secretion.[2][8]

See also

References

  1. ^
    PMID 3207999
    .
  2. ^
    S2CID 19082134
    .
  3. S2CID 27967032
    .
  4. PMID 2842163
    .
  5. S2CID 6258207
    .
  6. S2CID 39446719
    .
  7. S2CID 33325915
    .
  8. ^
    S2CID 145758823
    .
  9. S2CID 31931009
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Flesinoxan&oldid=1134946036"